Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community.

Objective: To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries - Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods: We compared the evolution of three tourism variables - tourist arrivals, tourist expenditure, and average length of stay - in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results: Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions: Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Caribbean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries.

This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021-2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021-2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021-2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021-2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing population-level strategies first, where most countries would reach break-even before 2030.

Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resultados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do tabagismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avaliados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Adoption of high technology medical imaging and hospital quality and efficiency: Towards a conceptual framework.

Measuring the value of medical imaging is challenging, in part, due to the lack of conceptual frameworks underlying potential mechanisms where value may be assessed. To address this gap, this article proposes a framework that builds on the large body of literature on quality of hospital care and the classic structure-process-outcome paradigm. The framework was also informed by the literature on adoption of technological innovations and introduces 2 distinct though related aspects of imaging technology not previously addressed specifically in the literature on quality of hospital care: adoption (a structural hospital characteristic) and use (an attribute of the process of care). The framework hypothesizes a 2-part causality where adoption is proposed to be a central, linking factor between hospital structural characteristics, market factors, and hospital outcomes (ie, quality and efficiency). The first part indicates that hospital structural characteristics and market factors influence or facilitate the adoption of high technology medical imaging within an institution. The presence of this technology, in turn, is hypothesized to improve the ability of the hospital to deliver high quality and efficient care. The second part describes this ability throughout 3 main mechanisms pointing to the importance of imaging use on patients, to the presence of staff and qualified care providers, and to some elements of organizational capacity capturing an enhanced clinical environment. The framework has the potential to assist empirical investigations of the value of adoption and use of medical imaging, and to advance understanding of the mechanisms that produce quality and efficiency in hospitals.

FROM TALK TO ACTION: POLICY STAKEHOLDERS, APPROPRIATENESS, AND SELECTIVE DISINVESTMENT.

OBJECTIVES: There is widespread commitment--at least in principle--to "evidence-informed" clinical practice and policy development in health care. The intention is that only "appropriate" care ought to be delivered at public expense. Although the rationale for an appropriateness agenda is widely endorsed, and methods have been proposed for addressing it, few published studies exist of contemporary policy initiatives which have actually led to successful disinvestment. Our objective was to explore whether the direct involvement of policy stakeholders could advance appropriateness and disinvestment. METHODS: Several collaborative engagements with policy stakeholders were undertaken to adapt and combine conceptual and empirical material related to appropriateness and disinvestment from the literature to create tools and processes for use in Canada and the province of Ontario in particular. RESULTS: By combining inputs from the literature with colloquial evidence from policy stakeholders, a definition of appropriateness was developed and, importantly, endorsed by all the provincial and territorial ministers of health in Canada. Second, a reassessment framework was successfully implemented for identifying priorities for selective disinvestment. CONCLUSIONS: When scientific evidence was combined with colloquial evidence from policy stakeholders, progress was made on the design and successful implementation of policies for appropriateness and disinvestment.

The relationship between hospital adoption and use of high technology medical imaging and in-patient mortality and length of stay.

PURPOSE: The purpose of this paper is to investigate the relationship between hospital adoption and use of computed tomography (CT) scanners, and magnetic resonance imaging (MRI) machines and in-patient mortality and length of stay. DESIGN/METHODOLOGY/APPROACH: This study used panel data (2007-2010) from 124 hospital corporations operating in Ontario, Canada. Imaging use focused on medical patients accounting for 25 percent of hospital discharges. Main outcomes were in-hospital mortality rates and average length of stay. A model for each outcome-technology combination was built, and controlled for hospital structural characteristics, market factors and patient characteristics. FINDINGS: In 2010, 36 and 59 percent of hospitals had adopted MRI machines and CT scanners, respectively. Approximately 23.5 percent of patients received CT scans and 3.5 percent received MRI scans during the study period. Adoption of these technologies was associated with reductions of up to 1.1 percent in mortality rates and up to 4.5 percent in length of stay. The imaging use-mortality relationship was non-linear and varied by technology penetration within hospitals. For CT, imaging use reduced mortality until use reached 19 percent in hospitals with one scanner and 28 percent in hospitals with 2+ scanners. For MRI, imaging use was largely associated with decreased mortality. The use of CT scanners also increased length of stay linearly regardless of technology penetration (4.6 percent for every 10 percent increase in use). Adoption and use of MRI was not associated with length of stay. RESEARCH LIMITATIONS/IMPLICATIONS: These results suggest that there may be some unnecessary use of imaging, particularly in small hospitals where imaging is contracted out. In larger hospitals, the results highlight the need to further investigate the use of imaging beyond certain thresholds. Independent of the rate of imaging use, the results also indicate that the presence of CT and MRI devices within a hospital benefits quality and efficiency. ORIGINALITY/VALUE: To the authors' knowledge, this study is the first to investigate the combined effect of adoption and use of medical imaging on outcomes specific to CT scanners and MRI machines in the context of hospital in-patient care.

Sustained public preferences on hospital performance across Canadian provinces.

OBJECTIVES: To compare the Canadian public's view of various components of hospital performance at two points in time, and to investigate differences across provinces. METHODS: Random telephone interviews were conducted across Canada in 2001 and again in 2004. Respondents were asked to rate the importance of 10 aspects of hospital performance including coordination, skills of providers, the use of technology, medical errors, and waiting times. Aggregate importance scores were estimated in 2001 and 2004 and compared using t-tests. Provincial comparisons were investigated using analysis of covariance (ANCOVA) with a Bonferroni correction of 0.005 (0.05/10). The covariates were sex, age, marital status, education, working status, and income. RESULTS: Public preferences were similar across provinces and consistent over the two periods; however, respondents from Quebec showed a pattern somewhat different in each year and over time. Overall, the importance scores in Quebec tended to be lower than those from the other provinces. Respondents from all provinces except Quebec ascribed the greatest value to 'skill of medical staff' in 2001 and 2004. Those from Quebec, however, gave the highest rating to 'skill of medical staff' in 2001 and 'medical errors' in 2004; the latter climbed from the 8th to the 1st place over time. All respondents gave 'waiting time for a non-emergency surgical procedure' the lowest score in both years, although its importance score increased a significant 18% between 2001 and 2004 excluding the responses from Quebec. Significant covariates were sex, marital status, and education. CONCLUSIONS: Public preferences can help inform the work of health care policy and decision makers, particularly that related to resource allocation decisions.

Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community

[ABSTRACT]. Objective. To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries – Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods. We compared the evolution of three tourism variables – tourist arrivals, tourist expenditure, and aver- age length of stay – in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environ- ments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results. Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions. Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Carib- bean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

[RESUMEN]. Objetivo. Evaluar si la introducción de una legislación integral sobre ambientes libres de humo tuvo algún efecto sobre el turismo en cuatro países de la Comunidad del Caribe (CARICOM): Barbados, Guyana, Jamaica y Trinidad y Tobago. Métodos. Comparamos la evolución de tres variables turísticas (llegada de turistas, gasto de los turistas y duración promedio de la estancia) en un país que ha establecido entornos libres de humo de tabaco (país tratado) con la evolución de estas variables en el mismo país si no se hubiera adoptado una legislación sobre ambientes libres de humo. Se empleó un método de control sintético para recrear este escenario contrafáctico mediante la construcción de un país sintético utilizando un promedio ponderado de varios países del grupo de donantes de CARICOM que no habían introducido una legislación relativa a entornos libres de humo durante el período analizado. Se cuantificó el efecto de los entornos libres de humo de tabaco sobre el tur- ismo como la diferencia entre las variables turísticas en el país tratado y el sintético. Para evaluar si el efecto estimado de los entornos libres de humo fue estadísticamente significativo, se compararon los efectos de la legislación en el país tratado con los efectos placebo en el grupo de donantes mediante la suposición de que se hubiese introducido una legislación integral sobre ambientes libre de humo en el mismo año que en el país tratado. Resultados. La implementación de entornos sin humo de tabaco no tuvo ningún efecto en la llegada de tur- istas, el gasto de los turistas o la duración promedio de la estancia en los cuatro países. Conclusiones. Nuestros hallazgos ofrecen una prueba sólida de que las políticas públicas que prohíben fumar en lugares públicos no afectan a las empresas de hospitalidad y turismo. Dada la importancia económica de esta industria en el Caribe, la evidencia local proporcionada por este estudio ayudará a contrarrestar eficaz- mente la interferencia de la industria tabacalera y avanzar hacia una Comunidad del Caribe libre de humo de tabaco.

[RESUMO]. Objetivo. Avaliar se a promulgação de uma lei antifumo abrangente afetou o turismo em quatro países da Comunidade do Caribe (CARICOM), a saber: Barbados, Guiana, Jamaica e Trinidad e Tobago. Métodos. Comparamos a evolução de três variáveis relacionadas ao turismo (desembarque de turistas, des- pesas de turistas e duração média da estadia) em um país que havia implementado ambientes livres de fumo (país tratado) com a evolução dessas variáveis no mesmo país se a lei antifumo não tivesse sido implemen- tada. Usamos um método de controle sintético para recriar esse contrafactual, construindo um país sintético usando uma média ponderada de vários países doadores da CARICOM que não promulgaram leis sobre ambientes livres de fumaça durante o período analisado. Quantificamos o efeito dos ambientes livres de fumo no turismo como a diferença entre as variáveis de turismo no país tratado e no país sintético. Para avaliar se o efeito estimado dos ambientes livres de fumo foi resultado do acaso, comparamos os efeitos da legislação do país tratado com os efeitos placebo no grupo de doadores, supondo que uma lei antifumo abrangente havia sido promulgada no mesmo ano que no país tratado. Resultados. A implementação de ambientes livres de fumo não afetou o desembarque de turistas, as despe- sas de turistas ou a duração média da estadia nos quatro países. Conclusões. Nossas constatações fornecem evidências robustas de que as políticas públicas que proíbem o fumo em locais públicos não afetam o setor de hospitalidade e turismo. Considerando a importância econômica desta indústria para o Caribe, as evidências locais fornecidas por este estudo ajudarão a com- bater efetivamente a interferência da indústria do tabaco e a avançar rumo a um Caribe livre do fumo.

Effect of comprehensive smoke-free legislation on the tourism industry in countries of the Caribbean Community / Efecto de una legislación integral sobre ambientes libres de humo en la industria del turismo en los países de la Comunidad del Caribe / Efeito de uma lei antifumo abrangente sobre a indústria do turismo em países da Comunidade do Caribe

ABSTRACT Objective. To assess whether the introduction of comprehensive smoke-free legislation affected tourism in four Caribbean Community (CARICOM) countries - Barbados, Guyana, Jamaica, and Trinidad and Tobago. Methods. We compared the evolution of three tourism variables - tourist arrivals, tourist expenditure, and average length of stay - in a country implementing smoke-free environments (treated country) with the evolution of these variables in the same country if smoke-free legislation had not been implemented. We used a synthetic control method to recreate this counterfactual scenario by constructing a synthetic country using a weighted average of several donor-pool CARICOM countries that did not introduce legislation on smoke-free environments during the period analyzed. We quantified the effect of the smoke-free environments on tourism as the difference between tourism variables in the treated and synthetic country. To assess whether the estimated effect of the smoke-free environments was the result of chance, we compared the effects of legislation in the treated country to placebo effects in the donor pool by assuming comprehensive smoke-free legislation was introduced in the same year as in the treated country. Results. Implementing smoke-free environments did not affect the arrival of tourists, tourism expenditure, or the average length of stay in the four countries. Conclusions. Our findings provide strong evidence that public policies banning smoking in public places do not affect hospitality and tourism businesses. Given the economic significance of this industry in the Caribbean, the local evidence provided by this study will help to effectively counteract interference by the tobacco industry and advance towards a smoke-free Caribbean.

RESUMEN Objetivo. Evaluar si la introducción de una legislación integral sobre ambientes libres de humo tuvo algún efecto sobre el turismo en cuatro países de la Comunidad del Caribe (CARICOM): Barbados, Guyana, Jamaica y Trinidad y Tobago. Métodos. Comparamos la evolución de tres variables turísticas (llegada de turistas, gasto de los turistas y duración promedio de la estancia) en un país que ha establecido entornos libres de humo de tabaco (país tratado) con la evolución de estas variables en el mismo país si no se hubiera adoptado una legislación sobre ambientes libres de humo. Se empleó un método de control sintético para recrear este escenario contrafáctico mediante la construcción de un país sintético utilizando un promedio ponderado de varios países del grupo de donantes de CARICOM que no habían introducido una legislación relativa a entornos libres de humo durante el período analizado. Se cuantificó el efecto de los entornos libres de humo de tabaco sobre el turismo como la diferencia entre las variables turísticas en el país tratado y el sintético. Para evaluar si el efecto estimado de los entornos libres de humo fue estadísticamente significativo, se compararon los efectos de la legislación en el país tratado con los efectos placebo en el grupo de donantes mediante la suposición de que se hubiese introducido una legislación integral sobre ambientes libre de humo en el mismo año que en el país tratado. Resultados. La implementación de entornos sin humo de tabaco no tuvo ningún efecto en la llegada de turistas, el gasto de los turistas o la duración promedio de la estancia en los cuatro países. Conclusiones. Nuestros hallazgos ofrecen una prueba sólida de que las políticas públicas que prohíben fumar en lugares públicos no afectan a las empresas de hospitalidad y turismo. Dada la importancia económica de esta industria en el Caribe, la evidencia local proporcionada por este estudio ayudará a contrarrestar eficazmente la interferencia de la industria tabacalera y avanzar hacia una Comunidad del Caribe libre de humo de tabaco.

RESUMO Objetivo. Avaliar se a promulgação de uma lei antifumo abrangente afetou o turismo em quatro países da Comunidade do Caribe (CARICOM), a saber: Barbados, Guiana, Jamaica e Trinidad e Tobago. Métodos. Comparamos a evolução de três variáveis relacionadas ao turismo (desembarque de turistas, despesas de turistas e duração média da estadia) em um país que havia implementado ambientes livres de fumo (país tratado) com a evolução dessas variáveis no mesmo país se a lei antifumo não tivesse sido implementada. Usamos um método de controle sintético para recriar esse contrafactual, construindo um país sintético usando uma média ponderada de vários países doadores da CARICOM que não promulgaram leis sobre ambientes livres de fumaça durante o período analisado. Quantificamos o efeito dos ambientes livres de fumo no turismo como a diferença entre as variáveis de turismo no país tratado e no país sintético. Para avaliar se o efeito estimado dos ambientes livres de fumo foi resultado do acaso, comparamos os efeitos da legislação do país tratado com os efeitos placebo no grupo de doadores, supondo que uma lei antifumo abrangente havia sido promulgada no mesmo ano que no país tratado. Resultados. A implementação de ambientes livres de fumo não afetou o desembarque de turistas, as despesas de turistas ou a duração média da estadia nos quatro países. Conclusões. Nossas constatações fornecem evidências robustas de que as políticas públicas que proíbem o fumo em locais públicos não afetam o setor de hospitalidade e turismo. Considerando a importância econômica desta indústria para o Caribe, as evidências locais fornecidas por este estudo ajudarão a combater efetivamente a interferência da indústria do tabaco e a avançar rumo a um Caribe livre do fumo.

Diabetes risk reduction in primary care: Evaluation of the Ontario Primary Care Diabetes Prevention Program.

OBJECTIVES: Lifestyle interventions can reduce type 2 diabetes risk. The Primary Care Diabetes Prevention Program (PCDPP) was implemented by the Government of Ontario to lower diabetes risk. This study first evaluated the program, and second used a validated tool to estimate a potential population impact if the program were implemented more broadly in the province. METHODS: PCDPP was implemented in six primary care settings serving communities with high mortality risk due to chronic diseases. In total, 1916 adults with prediabetes or metabolic syndrome were enrolled from January 2011 to December 2012. Body weight was the primary outcome variable, and was modeled using four time periods (i.e., baseline, 3rd, 6th and 9th month). The intervention effect was estimated using multilevel mixed-effects linear regression, and was stratified by gender and age. In the population impact analysis, a number needed to treat (NNT) for the intervention to prevent one case of diabetes and an absolute number of diabetes cases averted were estimated. RESULTS: Weight loss over 9 months was 7.5% (or 6.8 kg), with 7.4% (or 6.4 kg) in females and 8.6% (or 8.6 kg) in males. When modeled, changes in weight were all statistically significant. The models for male participants predicted, however, some gains in weight in the last 3 months of the program. Dropout rates were 26.8%, 46.8% and 63.0% at 3rd, 6th and 9th month respectively. Scaling up the program would produce an NNT of approximately 36 and would avert 6401 cases of diabetes in five years. CONCLUSION: PCDPP may represent a potentially effective tool for population-level diabetes risk reduction.

Case for investment in tobacco cessation: a population based analysis in low- and middle-income countries

[ABSTRACT]. This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021–2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021–2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021– 2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021–2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing popula- tion-level strategies first, where most countries would reach break-even before 2030.

[RESUMEN]. Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resul- tados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

[RESUMO]. Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do taba- gismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avali- ados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Case for investment in tobacco cessation: a population-based analysis in low- and middle-income countries / Argumentos a favor de la inversión en iniciativas para el abandono del tabaco: un análisis basado en la población en países de ingreso bajo y mediano / Análise de viabilidade de investimento na cessação do tabagismo: um estudo populacional em países de baixa e média renda

ABSTRACT This study aimed to estimate the return on investments of three population-level tobacco cessation strategies and three pharmacological interventions. The analysis included 124 low- and middle-income countries, and assumed a 10-year investment period (2021-2030). The results indicate that all six cessation programmes could help about 152 million tobacco users quit and save 2.7 million lives during 2021-2030. If quitters were followed until 65 years of age, 16 million lives could be saved from quitting. The combined investment cost was estimated at 1.68 United States dollars (US$) per capita a year, or US$ 115 billion over the period 2021-2030, with Caribbean countries showing the lowest investment cost at US$ 0.50 per capita a year. Return on investments was estimated at 0.79 (at the end of 2030) and 7.50 if benefits were assessed by the time quitters reach the age of 65 years. Disaggregated results by country income level and region also showed a return on investments less than 1.0 in the short term and greater than 1.0 in the medium-to-long term. In all countries, population-level interventions were less expensive and yielded a return on investments greater than 1.0 in the short and long term, with investment cost estimated at US$ 0.21 per capita a year, or US$ 14.3 billion over 2021-2030. Pharmacological interventions were more expensive and became cost beneficial over a longer time. These results are likely conservative and provide support for a phased approach implementing population-level strategies first, where most countries would reach break-even before 2030.

RESUMEN Este estudio tenía como objetivo estimar el rendimiento de la inversión de tres estrategias para el abandono del tabaco dirigidas a la población y de tres intervenciones farmacológicas. El análisis incluyó a 124 países de ingreso bajo y mediano y consideró que el período de inversión era de 10 años (2021-2030). Los resultados muestran que los seis programas sobre el abandono del tabaco podrían ayudar a unos 152 millones de personas a dejar el tabaco y salvar 2,7 millones de vidas en el período 2021-2030. Si se siguiera a las personas que dejan el tabaco hasta que cumpliesen 65 años, el número de vidas que se podrían salvar sería de 16 millones. Se estimó que el costo combinado de la inversión era de 1,68 dólares estadounidenses (US$) per cápita al año, o US$ 115 billones durante el período 2021-2030, y que el costo de inversión más bajo se encontraba en los países del Caribe (US$ 0,50 per cápita al año). Se estimó que el rendimiento de la inversión era de 0,79 (a finales de 2030) y de 7,50 si se tenían en cuenta los beneficios que obtienen las personas que dejan el tabaco hasta que alcanzan los 65 años. Los resultados desglosados por nivel de ingresos de los países y región también mostraron que el rendimiento de la inversión era inferior a 1,0 a corto plazo y superior a 1,0 de mediano a largo plazo. En todos los países, las intervenciones dirigidas a la población fueron menos costosas y produjeron un rendimiento de la inversión superior a 1,0 a corto y largo plazo, con un costo de las inversiones estimado en US$ 0,21 per cápita al año, o US$ 14,3 billones durante el período 2021-2030. Las intervenciones farmacológicas fueron más costosas y solo fueron generaron beneficios en función de los costos a más largo plazo. Probablemente son unos resultados prudentes, pero sirven de base para adoptar un enfoque gradual en la aplicación de estrategias dirigidas a la población primero donde la mayoría de los países alcanzarían el punto de equilibrio antes del 2030.

RESUMO Este estudo teve como objetivo estimar o retorno dos investimentos de três estratégias de cessação do tabagismo no nível populacional e de três intervenções farmacológicas. A análise incluiu 124 países de baixa e média renda e presumiu um período de investimento de 10 anos (2021-2030). Os resultados indicam que todos os seis programas de cessação poderiam ajudar cerca de 152 milhões de usuários de tabaco a parar de fumar e salvar 2,7 milhões de vidas entre 2021 e 2030. Se houvesse acompanhamento até os 65 anos de idade daqueles que parassem de fumar, 16 milhões de vidas poderiam ser salvas. O custo de investimento combinado foi estimado em 1,68 dólares americanos (US$) per capita por ano, ou US$ 115 bilhões no período 2021-2030, com os países do Caribe apresentando o menor custo de investimento, a US$ 0,50 per capita por ano. O retorno dos investimentos foi estimado em 0,79 (no fim de 2030) e 7,50 se os benefícios fossem avaliados até o momento em que aqueles que pararam de fumar chegassem aos 65 anos de idade. Os resultados desagregados por nível de renda nacional e por região também mostraram um retorno dos investimentos inferior a 1,0 no curto prazo e superior a 1,0 no médio e longo prazos. Em todos os países, as intervenções no nível populacional foram menos caras e renderam um retorno dos investimentos superior a 1,0 no curto e longo prazos, com um custo de investimento estimado em US$ 0,21 per capita por ano, ou US$ 14,3 bilhões entre 2021 e 2030. As intervenções farmacológicas foram mais caras e tiveram um bom custo-benefício durante um período mais longo. Estes resultados são provavelmente conservadores e servem de apoio para uma abordagem em fases que implemente primeiramente estratégias no nível populacional, onde a maioria dos países atingiria o ponto de equilíbrio antes de 2030.

Developing an efficient model to select emergency department patient satisfaction improvement strategies.

STUDY OBJECTIVE: Patient satisfaction is an important performance measure for emergency departments (EDs), but the most efficient ways of improving satisfaction are unclear. This study uses optimization techniques to identify the best possible combination of predictors of overall patient satisfaction to help guide improvement efforts. METHODS: The results of a satisfaction survey from 20,500 patients who visited 123 EDs were used to develop ordinal logistic regression models for overall quality of care, overall medical treatment, willingness to recommend the ED to others, and willingness to return to the same ED. Originally, 68,981 surveys were mailed, and 20,916 were returned, representing an overall response rate of 30.3%. We then incorporated these regressions into an optimization model to select the most efficient combination of predictors necessary to increase the 4 overall satisfaction measures by 5%. A sensitivity analysis was also conducted to explore differences across hospital peer groups and regions. RESULTS: Results differ slightly for each of the 4 overall satisfaction measures. However, 4 predictors were common to all of these measures: "perceived waiting time to receive treatment," "courtesy of the nursing staff," "courtesy of the physicians," and "thoroughness of the physicians." The selected predictors were not necessarily the strongest predictors identified through regression models. The optimization model suggests that most of these predictors must be improved by 15% to increase the overall satisfaction measures by 5%. CONCLUSION: This study introduces the use of optimization techniques to study ED patient satisfaction and highlights an opportunity to apply this technique to widely collected data to help inform hospitals' improvement strategies. The results suggest that hospitals should focus most of their improvement efforts on the 4 predictors mentioned above.

Acute care hospital strategic priorities: perceptions of challenges, control, competition and collaboration in Ontario's evolving healthcare system.

To explore the current and pending strategic agenda of Ontario hospitals (the largest consumers of the provincial healthcare budget), a survey of Ontario acute care hospital CEOs was conducted in January 2004. The survey, with an 82% response rate, identifies 29 strategic priorities under seven key strategic themes consistent across different hospital types. These themes include (1) human resources cultivation, (2) service integration and partnerships, (3) consumer engagement, (4) corporate governance and management, (5) organizational efficiency and redesign, (6) improved information use for decision-making, (7) patient care management. The extent to which an individual hospital's control over strategic resolutions is perceived may affect multilevel strategic priority-setting and action-planning. In addition to supporting ongoing development of meaningful performance measures and information critical to strategic decision-making, this study's findings may facilitate a better understanding of hospitals' key resource commitments, the extent of competition and collaboration for key resources, the perceived degree of individual control over strategic issue resolution and where systemic resolutions may be required.

The combined use of surgery and radiotherapy to treat patients with epidural cord compression due to metastatic disease: a cost-utility analysis.

Neoplastic metastatic epidural spinal cord compression is a common complication of cancer that causes pain and progressive neurologic impairment. The previous standard treatment for this condition involved corticosteroids and radiotherapy (RT). Direct decompressive surgery with postoperative radiotherapy (S + RT) is now increasingly being chosen by clinicians to significantly improve patients' ability to walk and reduce their need for opioid analgesics and corticosteroids. A cost-utility analysis was conducted to compare S + RT with RT alone based on the landmark randomized clinical trial by Patchell et al. (2005). It was performed from the perspective of the Ontario Ministry of Health and Long-Term Care. Ontario-based costs were adjusted to 2010 US dollars. S + RT is more costly but also more effective than corticosteroids and RT alone, with an incremental cost-effectiveness ratio of US$250 307 per quality-adjusted life year (QALY) gained. First order probabilistic sensitivity analysis revealed that the probability of S + RT being cost-effective is 18.11%. The cost-effectiveness acceptability curve showed that there is a 91.11% probability of S + RT being cost-effective over RT alone at a willingness-to-pay of US$1 683 000 per QALY. In practice, the results of our study indicate that, by adopting the S + RT strategy, there would still be a chance of 18.11% of not paying extra at a willingness-to-pay of US$50 000 per QALY. Those results are sensitive to the costs of hospice palliative care. Our results suggest that adopting a standard S + RT approach for patients with MSCC is likely to increase health care costs but would result in improved outcomes.

Where to focus efforts to improve overall ratings of care and willingness to return: the case of Tuscan emergency departments.

OBJECTIVES: Both regression and optimization models were used to identify an efficient combination of aspects of care (e.g., comfort of waiting room) necessary to improve global emergency department (ED) patient satisfaction. The approach, based on patient survey data, tends to favor aspects of care with large regression coefficients and those whose current performance is low, because improvements produce a greater effect on global satisfaction. METHODS: The authors used ED patient satisfaction survey data collected between September and October 2007 from a random sample of 5,277 adult patients who visited 43 EDs in Tuscany, Italy. Ordinal logistic regression models were run to predict overall ratings of care and willingness to return using 20 independent variables (i.e., aspects of care). An optimization model was run to increase these two global items to a maximum of 15%. This model minimizes the total combined percentage increase of the aspects of care. Models using all cases (n = 5,277), cases from local hospitals (n = 4,264), and cases from teaching hospitals (n = 1,013) were run. RESULTS: Four aspects selected by the optimization algorithm were in all models: "satisfaction with waiting time,""comfort of the waiting room,""professionalism of physicians" (technical skills), and "level of collaboration between physicians and nursing staff." Most aspects needed a 15% increase to comply with the percentage increases set for the global satisfaction items. The model found that to increase overall ratings of care by 1, 2, or 8%, hospitals would need to focus only on one aspect: "level of collaboration between physicians and nursing staff." The total number of variables increased to six when the improvement in overall ratings of care was set at 15%. To increase 3 or 5% willingness to return, the optimization algorithm found that 6 or 14 aspects, respectively, are needed. An increase of 6% or more was unfeasible. CONCLUSIONS: This approach is only somewhat efficient, as a cost structure is absent. The optimization model assumes that the cost to increase each aspect by 1% is equivalent. By applying this modeling technique we have demonstrated that, at least, two elements are important to consider when developing efficient improvement strategies to increase global satisfaction: 1) the current level of satisfaction of the aspects of care and 2) the importance ascribed to the aspects of care. A third element, the cost to increase the aspects of care, might also be important. However, the impact of this element on the optimal solution is currently unknown.

CEO compensation and hospital financial performance.

Growing interest in pay-for-performance and the level of chief executive officers' (CEOs') pay raises questions about the link between performance and compensation in the health sector. This study compares the compensation of nonprofit hospital CEOs in Ontario, Canada to the three longest reported and most used measures of hospital financial performance. Our sample consisted of 132 CEOs from 92 hospitals between 1999 and 2006. Unbalanced panel data were analyzed using fixed effects regression. Results suggest that CEO compensation was largely unrelated to hospital financial performance. Inflation-adjusted salaries appeared to increase over time independent of hospital performance, and hospital size was positively correlated with CEO compensation. The apparent upward trend in salary despite some declines in financial performance challenges the fundamental assumption underlying this article, that is, financial performance is likely linked to CEO compensation in Ontario. Further research is needed to understand long-term performance related to compensation incentives.

Comparing patient reports about hospital care across a Canadian-US border.

OBJECTIVE: To compare patient reports about hospital care between western New York State and southern Ontario using a random intercept model. METHOD: Cross-sectional survey of 3923 patients who received medical or surgical care between August and October 2004 at 28 hospitals (14 hospitals per jurisdiction). Thirty-five questions were combined to calculate eight indicators with scores ranging from 0 to 100 (best care experience). For each indicator, a model was built where the region (western New York vs. southern Ontario) was included as a fixed effect with hospital as random within region. A number of patient characteristics were also included as fixed effects. RESULTS: The effect of the region was statistically significant (P < 0.05) only for the models predicting the 'continuity and transition', 'involvement of family' and 'physical comfort' indicator scores. The differences were 10.66, 4.05 and -3.23 points, respectively. In all three models, the random intercepts were not statistically significant, indicating that the differences above did not vary by hospitals. The model predicting 'overall impression' scores, however, showed a random intercept statistically significant (P = 0.026). The individual-level explained proportion of variance ranged from 5.68 to 11.22%, and the hospital-within-region-level explained proportion of variance ranged from 2.19 to 52.28%. CONCLUSION: The difference observed on the 'continuity and transition' indicator might be the only one somewhat meaningful, and might be explained by health maintenance organization reimbursements' mechanisms and hospital quality improvement initiatives available in western New York, as well as by the fact that occupancy rates in western New York border the 60% compared with the 95% in southern Ontario.

Factors that influence cancer patients' overall perceptions of the quality of care.

OBJECTIVE: This study outlines predictors of cancer patients' overall perceptions of the quality of care. DESIGN AND SETTING: Our sample included 2790 patients who received cancer care services during 2004 in 15 comprehensive cancer programmes across Ontario, Canada. Patients were classified into three groups: those receiving both chemotherapy and radiotherapy (n = 752), those receiving only chemotherapy (n = 1044), and those receiving only radiotherapy (n = 994). An ordinal logistic regression model for each patient group was performed to determine which variables most affected the probabilities of the patients' overall evaluations of the quality of care. Potential control variables were patients' age, sex, type of cancer, self-assessed health, and who completed the survey. RESULTS: Among seven common predictors of the overall quality perception across the three models, four should be of particular interest because patients perceived them as relatively problematic aspects of care. These are 'was informed about follow-up care after completing treatment', 'knew next step in care', 'knew who to go to with questions', and 'providers were aware of test results'. These predictors explained between 25 and 34% of the variance (depending on the model) of the overall perception of quality. The explanatory power of these predictors did not change across sex and age group. 'Self-assessed health' was the only control variable that remained in all three models. CONCLUSIONS: From a practical perspective, improvement efforts are best focused on factors that are strong predictors as well as on those for which there is a low score. Thus, on the basis of this study, practitioners' improvement efforts might be constructively focused on the four predictors mentioned above.